Palvella Completes Enrollment in Phase 3 SELVA Trial

Palvella Therapeutics ( (PVLA) ) has issued an update.

Palvella Therapeutics reported its second quarter 2025 financial results and provided a corporate update, highlighting the completion of enrollment in the Phase 3 SELVA trial for QTORIN rapamycin, which exceeded its target by over 25%. The company is on track for top-line results in early 2026 and plans to announce new development programs by the end of 2025. With cash reserves of $70.4 million, Palvella expects to fund operations into the second half of 2027, supporting its strategic agenda and growth in the rare disease market.

The most recent analyst rating on (PVLA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

Palvella Therapeutics’ overall score reflects significant financial challenges, particularly in revenue and profitability, which are partially offset by a robust cash position and no debt. Positive corporate developments, such as clinical advancements and strategic financing, provide potential growth opportunities. However, valuation concerns due to negative earnings and the absence of dividends weigh on the score.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare genetic skin diseases, for which there are no FDA-approved therapies. The company is advancing a pipeline of product candidates based on its patented QTORIN platform, with a primary focus on lifelong rare genetic skin diseases.

Average Trading Volume: 129,578

Technical Sentiment Signal: Hold

Current Market Cap: $477.7M

Find detailed analytics on PVLA stock on TipRanks’ Stock Analysis page.